Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy

Bhoopathi, Praveen; Padmanabhan, M.; Das, Swadesh K.; Fisher, Paul B.; Emdad, Luni

doi:10.1016/bs.acr.2023.02.010

Cited by 6 publications

(1 citation statement)

References 241 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pancreatic cancer is characterised by high heterogeneity between and within tumours, especially in terms of genetic changes and microenvironment. The drug resistance of pancreatic cancer patients to chemotherapy drugs is closely related to their heterogeneity 26 , 27 . Additionally, chromosomal instability and chromosomal aneuploidy are commonly present in human tumours 28 , 29 .…”

Section: Discussionmentioning

confidence: 99%

A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma

Tang,

Miao,

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Chemotherapy resistance poses clinical challenges in pancreatic cancer treatment. Developing cell lines resistant to chemotherapy is crucial for investigating drug resistance mechanisms and identifying alternative treatment pathways. The genetic and biological attributes of pancreatic cancer depend on its aetiology, racial demographics and anatomical origin, underscoring the need for models that comprehensively represent these characteristics. Here, we introduce PDAC-X2, a pancreatic cancer cell line derived from Chinese patients. We conducted a comprehensive analysis encompassing the immune phenotype, biology, genetics, molecular characteristics and tumorigenicity of the cell line. PDAC-X2 cells displayed epithelial morphology and expressed cell markers (CK7 and CK19) alongside other markers (E-cadherin, Vimentin, Ki-67, CEA and CA19-9). The population doubling time averaged around 69 h. In vivo, PDAC-X2 cells consistently maintained their tumorigenicity, achieving a 100% tumour formation rate. Characterised by a predominantly tetraploid karyotype, this cell line exhibited a complex genetic markup. Notably, PDAC-X2 cells demonstrated resistance to multiple drugs, including gemcitabine, paclitaxel, 5-fluorouracil and oxaliplatin. In conclusion, PDAC-X2 presents an invaluable preclinical model. Its utility lies in facilitating the study of drug resistance mechanisms and the exploration of alternative therapeutic approaches aimed at enhancing the prognosis of this tumour type.

show abstract